

Esophageal Cancer

Effective Date: June, 2021



Background

There are two common distinct histologies of esophageal cancer. Chronic gastroesophageal reflux predisposes to Barrett's metaplasia and the development of adenocarcinoma¹. Typically, it develops within the distal esophagus; in North America, it is now more prevalent than the other histology, squamous cell carcinoma². The recognized risk factors for squamous cell carcinoma include tobacco and alcohol exposure.³

Guideline Questions

1. What are the recommendations for the diagnostic workup of adult patients with esophageal cancer?
2. What are the recommendations for treatment of adult patients with potentially curable esophageal cancer?
3. What are the recommendations for management of adult patients with incurable esophageal cancer?

Search Strategy

This guideline was developed to promote evidence-based practice in Alberta. The following search criteria were used for the 2020 update using the pubmed database: (("oesophageal cancer"[All Fields] OR "esophageal neoplasms"[MeSH Terms] OR ("esophageal"[All Fields] AND "neoplasms"[All Fields]) OR "esophageal neoplasms"[All Fields] OR ("esophageal"[All Fields] AND "cancer"[All Fields]) OR "esophageal cancer"[All Fields]) AND phase[All Fields] AND III[All Fields]) AND (("2016/01/01"[PDAT] : "2019/07/01"[PDAT]) AND "humans"[MeSH Terms]) and ("oesophageal cancer"[All Fields] OR "esophageal neoplasms"[MeSH Terms] OR ("esophageal"[All Fields] AND "neoplasms"[All Fields]) OR "esophageal neoplasms"[All Fields] OR ("esophageal"[All Fields] AND "cancer"[All Fields]) OR "esophageal cancer"[All Fields]) AND "Radiotherapy"[All Fields] AND ("chemoradiotherapy"[MeSH Terms]) OR ("surgery"[All Fields]))

Target Population

The recommendations outlined in this guideline apply to adults over the age of 18 years with esophageal cancer, including both squamous cell and adenocarcinoma. Different principles may apply to pediatric patients.

Recommendations

Recommended Diagnostic Work-Up

- Esophagogastroduodenoscopy with biopsy establishes the tumour's location (distance from incisors) and histology.
- An augmented CT scan of the thorax, abdomen and pelvis also helps to establish the tumour's

location, depth of penetration into the esophageal wall, invasion into adjacent structures, and involvement of regional and non-regional lymph nodes. Metastatic disease confers an incurable situation for which only palliative maneuvers would be appropriate.

- Blood work identifies any end-organ dysfunction that may preclude the safe administration of chemotherapy.
- if no metastatic disease is seen on the baseline CT, F-fluorodeoxy-D-glucose (FDG) PET scan can complement an augmented CT scan and help to identify radiologically-occult metastatic disease⁴⁻⁶.

Optional Investigations:

- In the absence of metastatic disease (based upon the above investigations), the following tests may be of additional value if it would influence treatment decisions:
 - Bronchoscopy if tumor is located at or above the level of the carina.⁵¹⁻⁵³
 - Endoscopic ultrasound (establishes the depth of penetration into the esophageal wall, invasion into adjacent structures, and involvement of regional and non-regional lymph nodes) for clinically node negative, T1 or T2 tumors.⁵¹⁻⁵⁴
 - Pulmonary function testing (required prior to surgical resection and may be necessary prior to chemoradiotherapy).
- Bone scans can be done for patients suspected of having bone metastases, CT head or MRI for patients suspected of having brain metastases

Stage Information

Tumors involving the esophagogastric junction (EGJ) with the tumor epicenter no more than 2 cm into the proximal stomach are staged as esophageal rather than gastric cancers. In contrast, EGJ tumors with their epicenter located more than 2 cm into the proximal stomach are staged as stomach cancers (refer to gastric cancer guideline).

Table 1. AJCC Staging System for Esophageal Cancer, Eighth Edition¹³.

Definitions	
<p>Depth of Tumour Penetration (T Stage):</p> <p>T₀ No evidence of primary tumor</p> <p>T_{is} Carcinoma <i>in situ</i> or high-grade dysplasia</p> <p>T₁ Tumor invades the lamina propria, muscularis mucosae, or submucosa</p> <p>T_{1a} Tumor invades the lamina propria or muscularis mucosae</p> <p>T_{1b} Tumor invades the submucosa</p> <p>T₂ Invasion into muscularis propria</p> <p>T₃ Invasion into adventitia</p> <p>T₄ Tumor invades adjacent structures</p> <p>T_{4a} Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum</p> <p>T_{4b} Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway</p>	<p>Distant Metastasis (M Stage):</p> <p>M₀ No distant metastasis</p> <p>M₁ Distant metastasis</p> <p>Histologic Grade (G Stage):</p> <p>G₁ Well differentiated</p> <p>G₂ Moderately differentiated</p> <p>G₃ Poorly differentiated, undifferentiated</p> <p>Location of Squamous Cell Carcinomas:</p> <p>U Upper esophagus (20 to 25 cm from incisors)</p> <p>M Middle esophagus (>25 to 30 cm from incisors)</p> <p>L Lower esophagus (>30 to 40 cm from incisors)</p> <p>EGJ <i>Use this staging system if the tumour arises from the esophagogastric junction or from the stomach within 5 cm from esophagogastric junction and crosses the esophagogastric junction. Use the staging system for</i></p>

Regional* Lymph Node Involvement (N Stage): N ₀ No regional lymph node involvement N ₁ Involvement of one or two regional lymph nodes N ₂ Involvement of three to six regional lymph nodes N ₃ Involvement of seven or more regional lymph nodes						<i>gastric cancer for all other tumours (epicenter in stomach more than 5 cm from the esophagogastric junction and without extension into esophagus).</i>					
Squamous Cell Carcinoma (Clinical)						Adenocarcinoma (Clinical)					
Stage	T	N	M	G	L	Stage	T	N	M	G	
Stage 0	is	0	0	NA	NA	Stage 0	is	0	0	NA	
Stage I	1	0-1	0	NA	NA	Stage I	1	0	0	NA	
Stage II	2	0-1	0	NA	NA	Stage II_A	1	1	0	NA	
	3	0	0	NA	NA	Stage II_B	2	0	0	NA	
Stage III	3	1	0	NA	NA	Stage III	2	1	0	NA	
	1-3	2	0	NA	NA		3	0-1	0	NA	
Stage IV_A	4	0-2	0	NA	NA	4a	0-1	0	NA		
Stage IV_B	Any	3	0	NA	NA	Stage IV_A	1-4a	2	0	NA	
Stage IV_C	Any	Any	1	NA	NA		4b	0-2	0	NA	
						Stage IV_B	Any	3	0	NA	
							Any	Any	1	NA	
Squamous Cell Carcinoma (Pathological)						Adenocarcinoma (Pathological)					
Stage	T	N	M	G	L	Stage	T	N	M	G	
Stage 0	0	0	0	NA	Any	Stage 0	is	0	0	NA	
Stage I_A	0	0	1	1	Any	Stage I_A	1a	0	0	1	
	1a	0	0	X	Any		1a	0	0	X	
Stage I_B	1a	0	0	2-3	Any	Stage I_B	1a	0	0	2	
	1b	0	0	1-3	Any		1b	0	0	1-2	
	1b	0	0	X	Any		1b	0	0	X	
Stage II_A	2	0	0	1	Any	Stage I_C	1	0	0	3	
	2	0	0	2-3	Any		2	0	0	1-2	
	3	0	0	X	Any	Stage II_A	2	0	0	3	
	3	0	0	Any	L		2	0	0	X	
Stage II_B	3	0	0	1	U/M	Stage II_B	1	1	0	Any	
	3	0	0	2-3	U/M		3	0	0	Any	
	3	0	0	X	Any	Stage III_A	1	2	0	Any	
	3	0	0	Any	X		2	1	0	Any	
Stage III_A	1	1	0	Any	Any	Stage III_B	2	2	0	Any	
	1	1	0	Any	Any		3	1-2	0	Any	
	2	1	0	Any	Any		4a	0-1	0	Any	
Stage III_B	2	2	0	Any	Any	Stage IV_A	4a	2	0	Any	
	2	1-2	0	Any	Any		4b	0-2	0	Any	
	4a	0-1	0	Any	Any	Stage IV_A	Any	3	0	Any	
Stage IV_A	4a	2	0	Any	Any	Stage IV_B	Any	Any	1	Any	
	4b	0-2	0	Any	Any						
	Any	3	0	Any	Any						
Stage IV_B	Any	Any	1	Any	Any						

Goals of Therapy

To render the patient free of disease, to relieve symptoms (e.g.: dysphagia), and to improve or prolong survival, if possible.


Recommendations¹⁴:

- Complete the work-up (as described above).
- For patients who do not have metastatic disease:
 - Early referral to a surgeon trained in esophageal surgery is important to assess for resectability.
 - Patients should be referred for a multidisciplinary discussion including radiation oncologists and medical oncologists prior to surgery for patients with resectable disease.
- Assess the degree of dysphagia and consult with a dietician to optimize the patient's nutritional status. Consider placement of a nasogastric (NG) feeding tube. If the NG feeding tube insertion is technically difficult, placement should be performed radiographically.
- In a curative situation, avoid placement of an endoluminal stent as it increases the complication and mortality rate with radical chemoradiotherapy¹⁵.
- Patients who receive preoperative chemoRT should have a CT scan prior to surgery. In certain cases, FDG-PET can provide an assessment of response but should only be done if clinically warranted⁷⁻¹².
- There is limited data to support the use of imaging after definitive chemoRT or after surgical resection for non-metastatic patients, however, individualized discussion regarding imaging after definitive chemoRT or after surgical resection for non-metastatic patients may be appropriate in select clinical cases.
- For patients on palliative systemic treatment, CT chest, abdomen, and pelvis should be done every 2-3 months depending on the clinical situation.
- Consider treatment on a clinical trial, if available.

Table 2. Modified dysphagia score.

Modified Dysphagia Score ¹⁶	
0	Ability to eat normal diet
1	Ability to eat some solid food
2	Ability to eat semisolids only
3	Ability to swallow liquids only
4	Complete dysphagia

Figure 1: Operable esophagogastric cancer clinical stage II-III¹⁷⁻²¹.



* Multidisciplinary discussion regarding chemoRT vs chemotherapy recommended

For gastric cancers, refer to the [Gastric Cancer Guidelines](#).

For more details, refer to table 2.

Note: EGJ was redefined in the AJCC 8th edition: adenocarcinomas with epicenters no more than 2cm into the gastric cardia are staged as esophageal adenocarcinomas, and those extending further are staged as stomach cancers.⁵⁵

Table 3. Curative therapy recommendations for patients with esophageal cancer.

Stage	Recommendations
T _{is} N ₀ or T _{1a} N ₀ Disease	<p>Preferred</p> <p>Endoscopic Therapy for Superficial Cancers:</p> <ul style="list-style-type: none"> Endoscopic mucosal resection (EMR)²², submucosal dissection (ESD) and various ablation techniques (e.g.: photo-dynamic therapy²³, argon plasma coagulation, radiofrequency ablation²⁴, cryotherapy) can preserve the integrity of the esophagus and provide a potentially curative option for superficial cancers. Provided careful endoscopic surveillance can be performed, consider for patients with favorable mucosal tumours* who are interested in an esophagus-sparing approach or who are elderly, with multiple comorbidities, or otherwise high surgical risk. <p>*Note: Favorable mucosal tumours include non-invasive (<i>in situ</i>) lesions or disease that invades into the mucosa (but <i>not</i> submucosa).</p>

		<table border="1"> <thead> <tr> <th>Stage</th> <th>Description</th> <th>Chance of Lymph Node Involvement</th> </tr> </thead> <tbody> <tr> <td>T_{is} (m1)</td> <td>Presence in the epithelial layer of the mucosa</td> <td>0%</td> </tr> <tr> <td>T_{1a} (m2)</td> <td>Invasion into lamina propria mucosal</td> <td>0%</td> </tr> <tr> <td>T_{1a} (m3)</td> <td>Invasion into (not through) muscularis mucosae</td> <td>7%</td> </tr> <tr> <td>T_{1b} (sm1)</td> <td>Invasion into superficial third of submucosa</td> <td>15%</td> </tr> <tr> <td>T_{1b} (sm2)</td> <td>Invasion into middle third of submucosa</td> <td>27%</td> </tr> <tr> <td>T_{1b} (sm3)</td> <td>Invasion into deepest third of submucosa</td> <td>49%</td> </tr> </tbody> </table>	Stage	Description	Chance of Lymph Node Involvement	T _{is} (m1)	Presence in the epithelial layer of the mucosa	0%	T _{1a} (m2)	Invasion into lamina propria mucosal	0%	T _{1a} (m3)	Invasion into (not through) muscularis mucosae	7%	T _{1b} (sm1)	Invasion into superficial third of submucosa	15%	T _{1b} (sm2)	Invasion into middle third of submucosa	27%	T _{1b} (sm3)	Invasion into deepest third of submucosa	49%
Stage	Description	Chance of Lymph Node Involvement																					
T _{is} (m1)	Presence in the epithelial layer of the mucosa	0%																					
T _{1a} (m2)	Invasion into lamina propria mucosal	0%																					
T _{1a} (m3)	Invasion into (not through) muscularis mucosae	7%																					
T _{1b} (sm1)	Invasion into superficial third of submucosa	15%																					
T _{1b} (sm2)	Invasion into middle third of submucosa	27%																					
T _{1b} (sm3)	Invasion into deepest third of submucosa	49%																					
	Alternate	<p>Esophagectomy:</p> <ul style="list-style-type: none"> Resect disease if both technically and medically feasible. Aim to achieve an “R₀” resection (no gross or microscopic residual tumour). Post-operative morbidity and survival are significantly better when surgery is completed in an experienced centre²⁵. 																					
T _{1b} N ₀ Disease	Preferred	<p>Esophagectomy:</p> <ul style="list-style-type: none"> Esophagectomy is the preferred treatment choice for fit patients with superficial esophageal cancers invading the submucosa. 																					
	Alternate	<p>Endoscopic therapy:</p> <ul style="list-style-type: none"> For most patients with favorable intramucosal tumors, who are interested in an esophagus-sparing approach or are older with multiple comorbidities or are otherwise high surgical risk are candidates for endoscopic resection rather than surgical resection. If a patient is not medically operable, declines surgery, or is not a candidate for EMR/ESD, refer to Table 3 																					
T ₂ , T ₃ , N ₊ , M ₀ Disease*	Preferred	<p>Pre-Operative Chemoradiotherapy followed by Esophagectomy (if possible):</p> <ul style="list-style-type: none"> CROSS pre-operative chemoradiation (Level 1 evidence): Deliver 4,140 cGy in twenty-three fractions over five weeks plus Paclitaxel 50 mg/m² IV and Carboplatin AUC 2 IV on days 1, 8, 15, 22, and 29¹⁷. This protocol improves the R₀ resection rate (92% versus 69%) and overall survival (HR 0.657, CI_{95%} 0.495-0.871, p = 0.003) when compared to surgery alone. It prolongs median survival from 24.0 months to 49.4 months and increases the one-, two-, three-, and five-year survival rates from 70% to 82%, 50% to 67%, 44% to 58%, and 34% to 47% respectively. It offers a pCR rate of 23%. 75% of the patients enrolled had adenocarcinoma. About 25% of patients had disease at the esophagogastric junction. Aim to achieve an “R₀” resection (no gross or microscopic residual tumour). Post-operative morbidity and survival are significantly better when surgery is completed in an experienced centre²⁵. Post-operative Adjuvant Therapy: <i>The Checkmate 577 trial randomized patients who received preoperative CROSS chemoradiotherapy followed by surgery with residual pathological disease (> ypT1 and/or >ypN1) to nivolumab (240 mg/m² IV q 2 weekly for up to 1 year) or placebo.</i> 																					

*Note that esophagectomy alone is an option in low risk cT2N0 patients.⁵⁶

		<p><i>Disease free survival (DFS) was significantly improved in the nivolumab group compared to the placebo (median 22.4 months versus 11.0 months, HR 0.69, 95% CI 0.56-0.86, p=0.003).⁴⁸ Nivolumab is not currently funded for this indication in Alberta.</i></p> <ul style="list-style-type: none"> • No randomized trial (and at least two meta-analyses^{26,27} has demonstrated a survival advantage for preoperative chemoradiotherapy over chemotherapy alone • One network meta-analysis concluded that there is a survival benefit for neoadjuvant chemoradiotherapy over neoadjuvant chemotherapy²⁸. <ul style="list-style-type: none"> ○ 31 randomized controlled trials involving 5496 patients were included in the quantitative analysis ○ Neoadjuvant chemoradiotherapy improved overall survival when compared to all other treatments including: <ul style="list-style-type: none"> ○ Surgery alone (HR 0.75, 95% CI 0.67-0.85) ○ Neoadjuvant chemotherapy (HR 0.83, 95% CI 0.70-0.96) and ○ Neoadjuvant radiotherapy (HR 0.82, 95% CI 0.67-0.99) • In the neoadjuvant setting, treatment with chemoradiotherapy yields higher rates of pCRs and R0 resections compared to chemotherapy. Chemoradiation is also of shorter duration and there is no need for a central line. Decisions regarding the optimal neoadjuvant therapeutic modality warrants a multidisciplinary discussion incorporating the planned surgery, tumor anatomy, patient wishes and comorbidities.
<p>T₂, T₃, or T_{4a} N₊, M₀ Disease</p>	<p style="writing-mode: vertical-rl; transform: rotate(180deg);">Chemotherapy</p>	<p>Peri-Operative Chemotherapy: Preferred: FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel, (Level 1 evidence) was superior to epirubicin, cisplatin and fluorouracil /capecitabine for resectable cT2 or cN1+ gastric and gastroesophageal adenocarcinomas. Patients with Siewart type 1 to 3 gastroesophageal adenocarcinoma comprised 56% of patients in the trial. Median survival with FLOT was 50 months versus 35 months with ECF/ECX HR 0.77(, CI_{95%} 0.63-0.94, p =0.012)¹⁸.</p> <ul style="list-style-type: none"> • Perioperative chemotherapy with FLOT consists of 4 cycles of chemotherapy prior to surgery with a further 4 cycles of chemotherapy post-surgery. Each cycle lasts 14 days and consists of 5-FU 2600 mg/m² (24 h) day 1 and leucovorin 200 mg/m² (2h), day 1 and oxaliplatin 85 mg/m² (2 h) day 1 and docetaxel 50 mg/m² (1 h), every 2 weeks. Prophylactic GCSF should be considered for patients undergoing FLOT, as grade 3/4 neutropenia occurs at a higher rate than ECF/ECX. <p>Note: The FLOT trial did not include esophageal cancers.</p> <p>Alternatives for patients not candidates for FLOT</p> <ul style="list-style-type: none"> • MAGIC: When compared to surgery alone in patients with good performance status (ECOG ≤1) and T₂₋₄N₀₋₃M₀ adenocarcinoma of the distal third of the esophagus, gastro-esophageal junction, or stomach, peri-operative chemotherapy improves the five-year progression-free (HR 0.66, CI_{95%} 0.53-0.81, p < 0.001) and overall survival (from 23.0% to 36.3%, HR 0.74, CI_{95%} 0.59-0.93, p = 0.008¹⁹). <ul style="list-style-type: none"> • <i>Pre-Operative Phase:</i> Three three-week cycles of Epirubicin 50 mg/m² and Cisplatin 60 mg/m² IV on day one plus a continuous intravenous infusion of 5-Fluorouracil 200 mg/m²/day over twenty-one days.

- *Operative Phase:* Perform surgical resection with oncologic principles.
- *Post-Operative Phase:* As described in the pre-operative phase (above).

Alternative for patients not candidates for epirubicin (MAGIC): cisplatin 5FU has been evaluated in patients with operable adenocarcinoma of the esophagus and gastroesophageal junction

- The FFCD trial six peri-operative cycles of Cisplatin and infusional fluorouracil improves the five-year disease-free survival (34% *versus* 19%, HR 0.65, CI_{95%} 0.48-0.89, $p = 0.003$), overall survival (38% *versus* 24%, HR 0.69, CI_{95%} 0.50-0.95, $p = 0.02$), and rate of curative resection (84% *versus* 73%, $p = 0.04$) compared to surgery alone. Chemotherapy was given every 4 weeks and was comprised of cisplatin 100 mg/m² IV on day one plus 5-Fluorouracil 800 mg/m²/day over days one through five days, every 28 days²⁹.
- The OE5 trial randomized patients to 4 cycles of ECX or 2 cycles of cisplatin and infusional fluorouracil prior to surgery. The pathological complete response rate was higher in the ECX arm compared to cisplatin/fluoruracil (11% vs 3%). However, there was no significant difference in overall survival (23.4 months vs 26.1 months, HR 0.90 0.77-1.05, $p = 0.19$)²¹
- These regimens require placement of a central venous catheter (CVC), peripherally inserted central catheter (PICC line), or port.
- For patients in whom it is not possible to resect disease due to medical or technical issues, refer to Table 3

Table 3. Recommendations for patients with esophageal cancer who are not candidates for surgery.

Stage	Recommendations	
T ₁₋₄ N ₀₋₃	Preferred Recommendation	<p>In whom it is not possible to resect disease due to medical or technical issues:</p> <p>Primary ('Definitive') Chemoradiotherapy:</p> <ul style="list-style-type: none"> The two treatment options are: Preferred: Deliver 5,000 cGy in twenty-five fractions over five weeks plus Oxaliplatin 85 mg/m² IV and Leucovorin 200 mg/m² IV followed by 5-Fluorouracil 400 mg/m² IV bolus followed by 5-Fluorouracil 800 mg/m²/day over days one and two on weeks one, three, five, seven, nine, and eleven. This regimen is associated with less mucositis, alopecia, and renal toxicity plus numerically fewer toxic and sudden deaths but without a difference in overall survival, progression-free survival, and pCR rate ³⁰. (Level 1 evidence) Alternatively deliver 5,000 cGy in twenty-five fractions over five weeks plus Cisplatin 75 mg/m² IV over one hour and 5-Fluorouracil 4,000 mg/m² IV over ninety-six hours on weeks one, five, eight, and eleven. This protocol offers a five-year overall survival rate of 27% (compared to 0% for radiotherapy alone)³¹. <p>Note: 82% of the patients enrolled had squamous cell carcinoma of the esophagus.</p> <ul style="list-style-type: none"> These regimens require placement of a central venous catheter (CVC), peripherally inserted central catheter (PICC line), or port.
	Alternate	<p>Radiotherapy Alone:</p> <ul style="list-style-type: none"> Consider for patients who decline chemotherapy or in whom chemotherapy is deemed unsafe.

Recommendations for Incurable Situations

Provide palliative maneuvers to maintain and/or improve quality of life:

1. Relieve pain, bleeding, and/or dysphagia with radiotherapy (30 Gy in 10 fractions is preferred, alternatively 40 Gy in 15 fractions or 50 Gy in 20 fractions).
2. Consider placement of an endoluminal stent^{32,33} or photodynamic therapy³⁴ to relieve dysphagia.
3. Patients with advanced esophageal cancer who have a self-expanding metal stent inserted for the primary management of dysphagia do not gain additional benefit from concurrent palliative radiotherapy (Level 1 evidence). Palliative radiotherapy may be indicated for bleeding.⁴⁹
4. Consider palliative chemotherapy to control disease and prolong survival in patients with a satisfactory performance status (ECOG ≤ 2)³⁵⁻⁴¹
5. Consider treatment on a clinical trial if available.
6. Consider early referral to palliative care. (Symptom management guidelines can be found [here](#)).
7. Refer to dietitians and consider psychosocial referral. Early interdisciplinary care with the addition of psychologists and dietitians improved survival compared to standard oncology care in phase III trial of untreated patients with metastatic upper GI cancers (median overall survival 14.8 months vs 11.9 months, HR 0.68; 95% CI 0.51-0.9; = 0.021).⁵⁸

Table 4. ECOG Performance Status Scale.

ECOG	Description of Performance Status
0	Fully active and able to carry on without restriction.
1	Unable to carry out physically strenuous activities but ambulatory and able to complete work of a light or sedentary nature.
2	Ambulatory and capable of all self-care but unable to complete work activities. Up and about more than 50% of waking hours.
3	Capable of only limited self-care and/or confined to a bed or chair for more than 50% of waking hours.
4	Completely disabled. Unable to carry out any self-care. Totally confined to a bed or chair.

Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Many phase III clinical trials for metastatic gastric cancer also included patients with adenocarcinoma of the gastroesophageal junction. By extrapolation, patients with metastatic adenocarcinoma of the esophagus and gastroesophageal junction are treated as per metastatic gastric cancers. [Link to [Gastric Guideline](#)].

Evaluation of HER2 protein expression via immunohistochemistry or in situ hybridization is recommended to select patients with metastatic esophageal/gastroesophageal adenocarcinoma for trastuzumab based treatment⁴².

Metastatic Squamous Cell Cancer of the Esophagus

There is limited data to guide systemic therapy for metastatic squamous cell cancer of the esophagus. The combination of a platinum with a fluoropyrimidine is the preferred first line regimen^{42,43}.

- Patients with squamous cell esophageal cancer comprised approximately 10% of patients in the REAL-2 trial. Capecitabine-based combination regimens (e.g.: ECX, EOX, CX) offer a superior response rate (45.6% *versus* 38.4%, OR 1.38, CI_{95%} 1.10-1.73, $p = 0.006$) and overall survival (HR 0.87, CI_{95%} 0.77-0.98, $p = 0.02$) when compared to 5-Fluorouracil-based combination chemotherapies (e.g.: ECF, EOF, CF).
- ECX offers a median survival of about ten months and a one-year survival of around 40%³³. It is administered in three-week cycles where Epirubicin (50 mg/m² IV over twenty minutes) and Cisplatin (60 mg/m² IV over one hour along with hydration) are administered on day one. Capecitabine (625 mg/m² PO Q12h) is administered for twenty-one consecutive days.
- If a patient is unable to tolerate oral medications but remains a candidate for palliative chemotherapy, consider ECF. It is administered in three-week cycles as for ECX but, instead of Capecitabine, 5-Fluorouracil (200 mg/m²/day) is administered as a continuous intravenous infusion through a central venous catheter (“CVC”) or a peripherally inserted central catheter (“PICC line”).
- In a separate analysis of the REAL-2 clinical trial, thromboembolic events occur in 11.4% of patients (9.4% are venous events and 2.0% are arterial events)⁴⁴. They undermine overall survival (7.4 months *versus* 10.5 months, HR 0.80, CI_{95%} 0.64-0.99, $p = 0.043$). When compared to Cisplatin, Oxaliplatin confers a lower risk for thromboembolic events. A meta-analysis confirmed that the use of Oxaliplatin reduced the risk of death (HR 0.88, CI_{95%} 0.78-0.99, $p = 0.04$), progression (HR 0.88, CI_{95%} 0.80-0.98, $p = 0.02$), and thromboembolism⁴⁵.
- Oxaliplatin based chemotherapy is a reasonable option. A phase II trial evaluated FOLFOX (100) in metastatic squamous cell cancer of the esophagus. The response rate was 23.2% with a median overall survival of 7.7 months⁴⁶.
- *Preliminary data from the KEYNOTE-590 trial has demonstrated promising results. The trial randomized patients with advanced esophageal carcinoma (adenocarcinoma or squamous, N=749) to Pembrolizumab plus cisplatin/infusional 5FU chemotherapy versus chemotherapy alone. After a median follow-up of 10.8 months, Pembrolizumab + chemo demonstrated superior OS in ESCC patients (median OS 12.6 mo vs. 9.8 mo; HR: 0.72; 95%CI: 0.43-0.75; $p < 0.001$). The benefit was seen in all patients, but primarily driven by the patients with squamous cell cancer.⁵⁰ Pembrolizumab is not currently funded for this indication in Alberta.*

Second Line Therapy^{A7}

The ATTRACTION-3 study randomized patients with advanced esophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy to nivolumab versus chemotherapy of physician's choice (paclitaxel 100 mg/m² q week for 6 weeks followed by 1 week off) or docetaxel (75 mg/m² q3 weeks). Overall survival was significantly improved in the nivolumab group compared to chemotherapy (median 10.9 months versus 8.4 months, HR 0.77, 95% CI 0.62-0.96; p=0.019). There was no significant difference in progression free survival for nivolumab versus chemotherapy (median 1.7 months versus 3.4 months, HR 1.08, 95% CI 0.87–1.34). The prespecified interaction analysis indicated no significant interaction of treatment effect by PD-L1 status. Nivolumab is not currently available on the Alberta CancerCare Drug Benefit List.

Taxane based chemotherapy would be a reasonable alternative option and is available through [the Alberta CancerCare Drug Benefit List](#).

References

1. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999 Mar 18;340(11):825-831.
2. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. *Cancer* 1998 Nov 15;83(10):2049-2053.
3. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. *Semin Oncol* 1999 Oct;26(5 Suppl 15):2-8.
4. van Westreenen HL, Westerterp M, Bossuyt PM, Pruijm J, Sloof GW, van Lanschot JJ, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. *J Clin Oncol* 2004 Sep 15;22(18):3805-3812.
5. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. *J Clin Oncol* 2000 Sep 15;18(18):3202-3210.
6. Meyers BF, Downey RJ, Decker PA, Keenan RJ, Siegel BA, Cerfolio RJ, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. *J Thorac Cardiovasc Surg* 2007 Mar;133(3):738-745.
7. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. *Ann Oncol* 2002 Mar;13(3):361-368.
8. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. *J Clin Oncol* 2001 Jun 15;19(12):3058-3065.
9. Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. *Eur J Nucl Med Mol Imaging* 2007 Dec;34(12):1925-1932.
10. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. *Lancet Oncol* 2007 Sep;8(9):797-805.
11. Jamil LH, Gill KR, Wallace MB. Staging and restaging of advanced esophageal cancer. *Curr Opin Gastroenterol* 2008 Jul;24(4):530-534.
12. Stahl M, Wilke H, Stuschke M, Walz MK, Fink U, Molls M, et al. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. *J Cancer Res Clin Oncol* 2005 Jan;131(1):67-72.
13. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. *Ann Surg Oncol* 2010 Jul;17(7):1721-1724.
14. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. *Lancet Oncol* 2007 Jun;8(6):545-553.
15. Nishimura Y, Nagata K, Katano S, Hirota S, Nakamura K, Higuchi F, et al. Severe complications in advanced esophageal cancer treated with radiotherapy after intubation of esophageal stents: a questionnaire survey of the Japanese Society for Esophageal Diseases. *Int J Radiat Oncol Biol Phys* 2003 Aug 1;56(5):1327-1332.
16. Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. *N Engl J Med* 1993 Oct 28;329(18):1302-1307.
17. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen, M I, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med* 2012 May 31;366(22):2074-2084.
18. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019 May 11;393(10184):1948-1957.
19. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde, C J, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006 Jul 6;355(1):11-20.
20. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011 May 1;29(13):1715-1721.
21. Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal

- adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. *The Lancet Oncology* 2017;18(9):1249-1260.
22. Ciocirlan M, Lapalus MG, Hervieu V, Souquet JC, Napoleon B, Scoazec JY, et al. Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus. *Endoscopy* 2007 Jan;39(1):24-29.
 23. Seewald S, Ang TL, Groth S, Zhong Y, Bertschinger P, Altorfer J, et al. Detection and endoscopic therapy of early esophageal adenocarcinoma. *Curr Opin Gastroenterol* 2008 Jul;24(4):521-529.
 24. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. *N Engl J Med* 2009 May 28;360(22):2277-2288.
 25. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. *N Engl J Med* 2002 Apr 11;346(15):1128-1137.
 26. Pasquali S, Yim G, Vohra RS, Mocellin S, Nyanhongo D, Marriott P, et al. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis. *Ann Surg* 2017 Mar;265(3):481-491.
 27. Deng HY, Wang WP, Wang YC, Hu WP, Ni PZ, Lin YD, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. *Eur J Cardiothorac Surg* 2017 Mar 1;51(3):421-431.
 28. Chan KKW, Saluja R, Delos Santos K, Lien K, Shah K, Cramarossa G, et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis. *Int J Cancer* 2018 Jul 15;143(2):430-437.
 29. Mariette C, Seitz J, Maillard E, Mornex F, Thomas P, Raoul J, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. *J Clin Oncol* 2010 ASCO Annual Meeting Proceedings 2010;28(15S):4005.
 30. Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *Lancet Oncol* 2014 Mar;15(3):305-314.
 31. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA* 1999 May 5;281(17):1623-1627.
 32. Saxon RR, Morrison KE, Lakin PC, Petersen BD, Barton RE, Katon RM, et al. Malignant esophageal obstruction and esophagorespiratory fistula: palliation with a polyethylene-covered Z-stent. *Radiology* 1997 Feb;202(2):349-354.
 33. Baron TH. Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. *N Engl J Med* 2001 May 31;344(22):1681-1687.
 34. Little VR, Luketich JD, Christie NA, Buenaventura PO, Alvelo-Rivera M, McCaughan JS, et al. Photodynamic therapy as palliation for esophageal cancer: experience in 215 patients. *Ann Thorac Surg* 2003;76(5):1687-1692.
 35. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. *Semin Oncol* 1999 Oct;26(5 Suppl 15):12-20.
 36. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008 Jan 3;358(1):36-46.
 37. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. *Ann Oncol* 2009 Sep;20(9):1529-1534.
 38. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *J Clin Oncol* 2002 Apr 15;20(8):1996-2004.
 39. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. *J Clin Oncol* 1997 Jan;15(1):261-267.
 40. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. *Br J Cancer* 1999 Apr;80(1-2):269-272.
 41. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol* 2006 Jun 20;24(18):2903-2909.
 42. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Ann Oncol* 2019 Jan 1;30(1):34-43.
 43. Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D, ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2016 Sep;27(suppl 5):v50-v57.

44. Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. *J Clin Oncol* 2009 Aug 10;27(23):3786-3793.
45. Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. *Gastric Cancer* 2011 Mar;14(1):50-55.
46. Wang J, Chang J, Yu H, Wu X, Wang H, Li W, et al. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. *Cancer Chemother Pharmacol* 2013 Apr;71(4):905-911.
47. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2019 Nov;20(11):1506-1517
48. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Cutsem EV, Piessen G, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N Engl J Med* 384: 1191-1203
49. Adamson D, Byrne A, Porter C, Blazeby J, Griffiths G, Nelson A, et al. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* Apr 2021; 6(4): 292-303
50. Kato K, Sun J, Shah MA, Enzinger PC, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. *ESMO 2020 Meeting, Abstract LBA8_PR*
51. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Collier S, Corvera C, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2021. *NCCN 2021; Mar*. Available: www.nccn.org/professionals/physician_gls/PDF/esophageal.pdf
52. Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 2016; 27(Suppl 5): doi:10.1093/annonc/mdw329
53. Cancer Care Ontario. Esophageal Cancer Diagnosis Pathway Map Version 2019.05. Available: www.cancercareontario.ca/sites/ccocancercare/files/assets/EsophagealDiagnosisPathway-2019-05.pdf
54. Fox M. T2N0 esophageal cancer-We can't know where to go unless we know where we've been. *J Thorac Cardiovasc Surg* 2019 Mar; 157(3): 1273-4
55. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. *Ann Cardiothorac Surg*. 2017 Mar; 6(2): 119-30
56. Esophageal Cancer Study Group Participating Centers. Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus. *J Thorac Cardiovasc Surg*. 2019 Mar; 157(3): 1264-72
57. Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y, Cao Y, et al. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. *J Clin Oncol*. 2021 Mar; 39(7): 748-56

Development and Revision History

This guideline was reviewed and endorsed by the Alberta GI Tumour Team. Members of the Alberta GI Tumour Team include surgical oncologists, radiation oncologists, medical oncologists, gastroenterologists, nurses, pathologists, and pharmacists. Evidence was selected and reviewed by a working group comprised of members from the Alberta GI Tumour Team, external participants identified by the Working Group Lead, and a Knowledge Management Specialist from the Guideline Resource Unit. A detailed description of the methodology followed during the guideline development process can be found in the [Guideline Resource Unit Handbook](#).

This guideline was originally developed in 2010.

Maintenance

A formal review of the guideline will be conducted in 2022. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.

Abbreviations

AJCC, American Joint Committee on Cancer; CF, cisplatin + 5-fluorouracil; CI, confidence interval; CT, computed tomography; CVC, central venous catheter; CX, cisplatin + Capecitabine; ECF, epirubicin + cisplatin + 5-fluorouracil; ECOG, Eastern Cooperative Oncology Group; ECX, epirubicin + cisplatin + Capecitabine; EMR, endoscopic mucosal resection; EOF, epirubicin + oxaliplatin + 5-fluorouracil; EOX, epirubicin + oxaliplatin + Capecitabine; FDG-PET, fluorodeoxy-D-glucose positron emission tomography; HR, hazard ratio; IV, intravenous; NG, nasogastric; OR, odds ratio; pCR, pathological complete response; PICC, peripherally inserted central catheter; TNM, tumour-node-metastasis.

Disclaimer

The recommendations contained in this guideline are a consensus of the Alberta Provincial GI Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.

Copyright © (2021) Alberta Health Services

This copyright work is licensed under the [Creative Commons Attribution-NonCommercial-NoDerivative 4.0 International license](#). You are free to copy and distribute the work including in other media and formats for non-commercial purposes, as long as you attribute the work to Alberta Health Services, do not adapt the work, and

abide by the other license terms. To view a copy of this license, see <https://creativecommons.org/licenses/by-nc-nd/4.0/>. The license does not apply to AHS trademarks, logos or content for which Alberta Health Services is not the copyright owner.

Funding Source

Financial support for the development of Cancer Care Alberta's evidence-based clinical practice guidelines and supporting materials comes from the Cancer Care Alberta operating budget; no outside commercial funding was received to support the development of this document.

All cancer drugs described in the guidelines are funded in accordance with the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents of Alberta, unless otherwise explicitly stated. For a complete list of funded drugs, specific indications, and approved prescribers, please refer to the [Outpatient Cancer Drug Benefit Program Master List](#).

Conflict of Interest Statements

Dr. Rachid Mohamed has nothing to disclose.

Dr. Diane Severin has nothing to disclose.

Dr. Colin Schieman has nothing to disclose.

Dr. Patricia Tang reports personal fees from Celgene, Genomic Health International, Amgen, Merck, Taiho Pharmaceutical, AstraZeneca, Pfizer, and Novartis.

Derek Tilley has nothing to disclose.

Dr. Clarence Wong reports grants from Alberta Innovates, personal fees from Allergan, personal fees from Medtronic, personal fees from Takeda, personal fees from Pendopharm, grants from Somagen, outside the submitted work.